Afamelanotide

Afamelanotide is a synthetic peptide and an analogue of the naturally occurring hormone alpha-melanocyte-stimulating hormone (α-MSH). It is primarily used in the treatment of certain skin disorders, particularly those related to photosensitivity.

Mechanism of Action

Afamelanotide works by binding to the melanocortin 1 receptor (MC1R) on melanocytes, which are the cells responsible for producing melanin. This binding stimulates the production of melanin, leading to increased pigmentation of the skin. The increased melanin provides a protective effect against ultraviolet radiation (UVR) from the sun, reducing the risk of photodamage and skin cancer.

Medical Uses

Afamelanotide is primarily used in the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder that causes severe photosensitivity. Patients with EPP experience painful reactions to sunlight, and afamelanotide helps to increase their tolerance to sunlight by enhancing skin pigmentation.

Erythropoietic Protoporphyria

In patients with EPP, afamelanotide is administered as a subcutaneous implant. The implant slowly releases the drug over time, providing a sustained increase in melanin production. This treatment has been shown to significantly improve the quality of life for EPP patients by allowing them to spend more time outdoors without experiencing pain.

Side Effects

Common side effects of afamelanotide include nausea, headache, and fatigue. Some patients may also experience skin darkening beyond the desired level. As with any medication, there is a risk of allergic reactions, although these are rare.

Development and Approval

Afamelanotide was developed by Clinuvel Pharmaceuticals, an Australian company. It was first approved for use in the European Union in 2014 and later received approval in the United States by the Food and Drug Administration (FDA) in 2019 for the treatment of EPP.

Research and Future Directions

Research is ongoing to explore the potential uses of afamelanotide in other conditions characterized by photosensitivity, such as polymorphous light eruption and solar urticaria. Additionally, there is interest in its use for vitiligo, a condition where loss of skin pigmentation occurs.

Related Pages

• Melanocyte
• Melanin
• Photosensitivity
• Erythropoietic protoporphyria
• Clinuvel Pharmaceuticals

Melanotan structure